Biotech Values

[DewDiligence]

GILD in-licenses BI’s “non-catalytic” HIV integrase inhibitors:

http://finance.yahoo.com/news/Gilead-and-Boehringer-bw-510896475.html?x=0&.v=1

The lead compound in this deal, BI 224436, is about to enter phase-1b. Non-catalytic integrase inhibitors bind to a different site on the HIV integrase from such II’s as MRK’s Isentress and GILD’s Elviegravir (a component of GILD’s ‘Quad’ combo pill).

Financial terms were not disclosed.